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mesenchymal transition. 16 IL-6 activation of STAT3 results in multiple cellular changes that promote malignancy by enhancing cell proliferation, stemness, survival, metastatic spread, and neovascularization. 17 Chronic production of IL-1 , TNF-, and IL-6 also facilitates the progression of cancer by inducing myeloid-derived suppressor cells (MDSC). [18] [19] [20] [21] [22] MDSC are profoundly immune-suppressive cells that use a variety of immune and nonimmune mechanisms to facilitate tumor growth by inhibiting innate and adaptive immunity, as well as by promoting angiogenesis and metastasis. [23] [24] [25] [26] Given earlier studies indicating that obesity increases MDSC levels in mice, 27 we hypothesized that the elevated levels of MDSC in obese individuals may be an important mechanism by which obesity facilitates cancer progression.
We have tested our hypothesis using mice fed a high fat diet (HFD) vs. a low fat diet (LFD), conditions that are known to produce obese and lean mice, respectively. 28 Our results demonstrate that MDSC induced by HFD are protective against some of the metabolic dysfunction associated with weight gain, while suppressing T cell function and increasing tumor progression. Mechanistically, the adipokine leptin, which regulates appetite satiety and is up-regulated in HFD mice, is responsible for driving the accumulation of MDSC. Hopkins University, Baltimore, MD, USA). Mice were fed chow with 60% energy derived from fat (HFD), or matched chow containing 10% of energy derived from fat (LFD) (Research Diets, Inc., New Brunswick, NJ, USA; D12492 and D12450J, respectively). Unless noted otherwise, "HFD" and "LFD" mice refer to groups that were maintained on a HFD or LFD, respectively, for a minimum of 8 wk. BALB/c-derived 4T1 tumor cells were maintained as described. 29 Mice were inoculated orthotopically in the abdominal mammary fat pad with 7 × 10 3 4T1 cells in 100 l DMEM. Primary tumors were measured with digital calipers as described. 29 Tumor volume = 4/3 r 3 (where r = ½ average of two perpendicular diameters). Survival time was recorded when mice became moribund and were euthanized. Metastatic disease was quantified as described using the clonogenic assay. 30 MDSC were obtained from the blood of tumor-free and 4T1-tumorbearing mice when tumors were ∼ 8-10 mm in diameter. MDSC from the blood of tumor-free mice were purified using anti-Gr1 antibody (RB6.8C5, IgG2b; BioXcell, (West Lebanon, NH, USA), magnetic beads, and LS columns (Miltenyi Biotech) as previously described. 31 Leukocyte content of RBC-depleted blood from 4T1-tumor-bearing mice typically contained 85-90% MDSC so further purification was not performed. MDSC from dissociated tumors were purified using a myeloid-derived suppressor cell purification kit (Miltenyi Biotech, Auburn, CA, USA). MDSC used in experiments were >85-90% Gr1 + CD11b + as assessed by flow cytometry. All animal procedures were approved by the UMBC Institutional Animal Care and Use Committee. Novolin-R human insulin was from ADW Diabetes Suppliers (Pompano Beach, FL, USA). Live cells were cell surface stained with Abs and analyzed on a Beckman/Coulter Cyan ADP flow cytometer using Summit v4.3 software as described. 32 Internal staining was performed following fixation with formaldehyde and permeabilization with saponin as described. 33 
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%CD11b + Ly6G + or CD11b + Ly6C + cells = (%CD11b + Ly6C + or %CD11b + Ly6G + )/(%CD11b + Ly6G + + %CD11b + Ly6C + )
Tumor, lung, and liver dissociations
Tumors were dissociated as previously described. 31 Briefly, resected tumors were minced, placed into GentleMACS C tubes (Miltenyi Biotech) with dissociation medium (DMEM with 300 U/ml collagenase IV, 0.1% hyaluronidase, and 2 kU/ml DNase I), processed on the GentleMACS dissociator, rotated (10 rpm; Glas-Col rotator) at 37C for 40 min, then processed twice on the GentleMACS dissociator.
Remaining debris was removed by passing through a 70-m mesh.
For some samples dead cells were removed by ficoll density gradient centrifugation. Livers were dissociated into a single cell suspension as described by Ma and coworkers 34 except Gey's solution was used to lyse RBC instead of ACK solution. Lungs were dissociated as previously described. 35 
MDSC and T cell depletions
Mice were MDSC-depleted or control antibody treated by twice weekly IP injection of 200 g Gr1 mAb (RB6-8C5; rat IgG2b) or isotype-matched control IgG (LTF-2; rat IgG2b), respectively, both from BioXcell. For CD4 + and CD8 + T cell depletions, mice were treated with GK1.5 plus 2.43 mAbs (100 l of each ascites or 200 g of purified mAb) i.p. on days -6, -3, and -1, followed by twice weekly injections for up to 8 wk until moribund. Depletion was confirmed by flow cytometry.
Fasting glucose and insulin tolerance
For the fasting glucose test, mice were fasted for 6 h and then blood glucose levels were measured using a One-Touch Ultra II glucometer (LifeScan, Johnson & Johnson). For insulin tolerance tests, mice were injected with insulin (0.75 IU/kg body weight diluted in PBS; 40-60 l/mouse) and blood glucose was measured using the OneTouch Ultra glucometer every 30 min over a 2 h period by collecting 1 drop of blood (∼50 l) from the tail vein. Area under the curve (AUC) for insulin tolerance was calculated using https://www.statstodo. com/index.php.
MDSC suppression
MDSC suppression of T cell activation was assayed as described. 29 Briefly, splenocytes from TcR transgenic mice were cultured with cognate peptide and tumor-infiltrating MDSC from 4T1-bearing BALB/c mice. Cultures were pulsed with 3 H-thymidine on day 3 and harvested on day 4. Supernatants from replicate plates without 3 H-thymidine were collected and analyzed for IFN-by ELISA (R&D Systems). For suppression assays in which PDL1 was blocked, PDL1 antibody (10F.9G2) was added to each well at 5.47 ng/ml. Percent
Leptin
Plasma leptin levels were assayed using a Quantikine anti-mouse and rat Leptin ELISA kit per the manufacturer's directions (MOB00; R&D).
Reactive oxygen species
Reactive oxygen species (ROS) production was measured by staining with dichlorodihydrofluorescein diacetate (DCFDA) as described. 29 Briefly, 1 × 10 6 MDSC were incubated in serum-free DMEM containing 0.2 M DCFDA for 20 min at 37 • C. Stained cells were washed twice with excess cold PBS and analyzed by flow cytometry.
T cell adoptive transfer and in vivo activation
CD8 + T cells were isolated from the spleens of OT-1 transgenic mice using an EasyStep Mouse CD8 + T Cell Isolation Kit (Stem Cell Technologies) and labeled using the CellTrace Violet Cell Proliferation Kit (Life Technologies, Carlsbad, CA) at a dye concentration of 5 mM, according to the manufacturers' protocol. Female C57BL/6 mice were adoptively transferred via the retro-orbital sinus with 5 × 10 6 to 1 × 10 7 violet-labeled CD8 + T cells in 100 l PBS. Twenty-four hours later, mice were injected in the retro-orbital sinus with cognate peptide (SIINFEKL, 50 g/100 l PBS). Forty-eight hours later, the mice were euthanized and their splenocytes stained and assayed by flow cytometry.
Inhibition of leptin receptor
BALB/c mice that had been maintained on a HFD for a minimum of 8 wk were inoculated daily for 3 consecutive days in the retro-orbital sinus with soluble mouse Leptin Receptor-Fc (Ob-R; Fc is IgG2a; R&D Systems) (100 g/200 l sterile PBS). Control mice were injected with an irrelevant recombinant protein (nonfunctional custom-made CD80-Fc) or IgG2a (R&D Systems). Seventy-two hours after the last injection, mice were bled and the level of circulating MDSC was assessed by flow cytometry.
IFN-induction of PDL1
Blood MDSC [(1-2) × 10 5 /well/200 l medium (HL1, 5 × 10 −5 Mmercaptoethanol, 1% penicillin/streptomycin, 1% glutamax, 1% gentamycin)] were incubated at 37 • C for ∼24 h. with 100 units/ml mouse IFN-. Cells were harvested, stained with antibodies to Gr1, CD11b, and PDL1, and the gated Gr1 + CD11b + cells analyzed for PDL1 expression by flow cytometry.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
Tumor or parametrial fat pads were dissected and immediately placed protocol. RNA concentrations were determined using a BioTek Synergy 2 microplate reader. cDNA was created from each RNA sample using the Maxima cDNA kit (Thermo Fisher). Transcripts were amplified using the KiCqStart SYBR Green qPCR ReadyMix, iQ (Sigma Life Science, Darmstadt, Germany) following the manufacturer's protocol, and detected using a CFX96 Real-Time PCR Detection System (BioRad). Each sample was analyzed in triplicate, and each primer set was tested by a melting curve. Relative expression of each experimental transcript was normalized to mRNA expression of the ribosomal protein L32 or -actin. 
Primers
RESULTS
HFD induces weight gain and increases the accumulation of immune-suppressive MDSC
Given the well-documented effects of nutritional overload on the risk and progression of breast cancer, we have focused our studies on females. Six-to-eight-week-old female BALB/c and C57BL/6 mice were started on a HFD or LFD and maintained on their respective diet for 12 wk. Prediet weights for the HFD and LFD groups of each strain were not significantly different ( Figure 1A) . Overall, the BALB/c postdiet LFD and HFD groups were 28.5% and 53.1% heavier than their prediet weights, respectively, and the C57BL/6 postdiet LFD and HFD groups were 34.8% and 126.2% heavier than their prediet weights, respectively, demonstrating that a HFD causes a greater weight gain than a LFD.
To determine if HFD impacted MDSC levels, prediet (6-8-wk-old) and postdiet (18-20- 7.8% and 13.8 ± 4.5% Gr1 + CD11b + cells, respectively). After being on their diets for 12 wk, LFD and HFD BALB/c mice contained 9.2% and 38.8% more total MDSC, respectively, than their prediet counterparts.
For the C57BL/6 HFD group, diet increased total MDSC by 19.7%, whereas for the C57BL/7 LFD group diet decreased total MDSC by 13.6%.
We also assessed levels of polymorphonuclear/granulocytic MDSC To determine if MDSC levels are impacted by weight, we plotted MDSC levels (percent blood Gr1 + CD11b + cells) of HFD and LFD mice as a function of weight ( Figure 1D ). For both BALB/c and C57BL/6 HFD mice, MDSC levels increased with increasing weight. In contrast, MDSC levels of LFD BALB/c and C57BL/6 mice remained unchanged or decreased with increased weight.
To confirm that the cells of HFD and LFD mice were immunesuppressive MDSC, Gr1 + CD11b + cells were magnetic bead purified from whole blood of HFD and LFD mice that had been on their diets for >12 wk and tested for their ability to suppress the proliferation of antigen-specific transgenic T cells, the hallmark of MDSC ( Figure 1E ).
Gr1 + CD11b + cells from both HFD and LFD mice were profoundly immune suppressive, identifying the cells as MDSC.
These results indicate that as mice on a HFD gain weight, MDSC levels in the blood also increase. Mice on a LFD also gain weight; however, their levels of circulating MDSC do not significantly increase, suggesting that a LFD protects against the accumulation of MDSC.
HFD-induced MDSC protect against metabolic dysfunction and reduce HFD-associated inflammation, but promote the accumulation of fat
Metabolic dysfunction is frequent in obese individuals or individuals consuming a HFD. Common problems include elevated fasting glucose levels and elevated insulin tolerance, which are characteristic of type II diabetes. 36 To determine if HFD-induced MDSC contribute to either of these metabolic dysfunctions, 6-8-wk-old female BALB/c and C57BL/6 mice were placed on a HFD or LFD for 8 wk. Some groups were also concurrently antibody depleted for MDSC or treated with an isotype-matched antibody as a control. At the end of the 8 wk, BALB/c and C57BL/6 HFD mice were significantly heavier than the LFD mice ( Figure 2A ). HFD mice of both strains had significantly higher fasting glucose levels ( Figure 2B ) and significantly increased insulin tolerance 
HFD-induced MDSC facilitate tumor progression by suppressing T cell activation
HFD increases the suppressive potency of tumor-infiltrating MDSC
Chronic inflammation is characteristic of obesity and HFD mice have elevated levels of the pro-inflammatory mediator TNF-in their adipose tissue ( Figure 2D ) and elevated levels of IL-6 in their blood. 27 To determine if heightened inflammation also exists in the tumor activity. This possibility was tested by PDL1 staining of blood MDSC from tumor-free HFD and LFD mice ( Figure 5C ) and blood and tumorinfiltrating MDSC from HFD and LFD mice carrying 4T1 tumors (Figure 5D) . Few blood MDSC from tumor-free HFD and LFD BALB/c mice expressed PDL1 (12.95 ± 3.08% and 14.06 ± 1.3%, respectively), and the percent of PDL1 + MDSC did not differ between HFD and LFD mice.
In contrast, 58.8 ± 11.4% of tumor-infiltrating MDSC in HFD mice 
Leptin-MDSC crosstalk regulates MDSC accumulation and leptin levels
Leptin is a pleiotropic molecule that regulates multiple metabolic, endocrine, and immunological functions, as well as impacting wound healing, angiogenesis, and hematopoiesis. It regulates the balance between food consumption and metabolism and is responsible for decreasing appetite. It is induced by pro-inflammatory mediators and is typically overexpressed in obese individuals who become nonresponsive to its effects. 38 To determine if MDSC and leptin impact each other, female BALB/c mice on a HFD or LFD were antibody depleted for MDSC or treated with an isotype control antibody and their levels of blood leptin measured by ELISA ( Figure 6A ). As expected, blood levels of leptin were elevated in HFD mice as compared to LFD mice.
MDSC-depleted HFD mice had significantly increased blood leptin levels, whereas the relatively low levels of leptin in LFD mice were not significantly affected by MDSC depletion. These results indicate that MDSC in HFD mice decrease leptin.
In addition to being induced by inflammation, leptin also contributes to inflammation by increasing T cell production of pro-inflammatory cytokines. 39, 40 Since MDSC are driven by inflammation, we hypothe- Collectively, these results demonstrate that leptin and MDSC engage in crosstalk in which leptin facilitates the accumulation of MDSC, while MDSC down-regulate the level of leptin.
DISCUSSION
Obesity is an established risk factor for developing cancer and is an indicator for poor prognosis for individuals with established cancer. 1, 4 Obesity drives multiple metabolic and endocrine abnormalities that contribute to cancer risk and cancer progression. In addition, obesity perturbs the immune system and polarizes macrophages and T cells toward a type 2 phenotype that favors tumor growth. 28 We now report another immune mechanism by which nutritional 26 Recent studies have also demonstrated that MDSC accumulate in pregnant women 41 and are essential for successful pregnancy in mice because they inhibit allo responses against genetically disparate fetuses. 42 These beneficial functions of MDSC are the result of their immune-suppressive activity and ability to counteract nondesirable immunity. The studies described here identify additional beneficial effects of MDSC. However, it is unclear whether the protection conferred by MDSC against metabolic dysfunction involves the immune-suppressive function of MDSC.
Effects of specific types of fat on various disease states have been investigated. In particular, the polyunsaturated fatty acid (PUFA) -linolenic acid (omega-3 fatty acid) is associated with a reduction in cardiovascular disease 43 and protection against some inflammatory and autoimmune diseases. 44 A recent study demonstrated that these PUFAs increase the accumulation and suppressive potency of MDSC, 45 consistent with the concept that these PUFAs reduce autoimmunity by promoting MDSC-mediated immune suppression. In contrast to diets high in PUFAs, the fat in the HFD used in the current studies consists of 26.5% polyunsaturated fat and 73.5% saturated and monosaturated fats. Therefore, PUFA, saturated, and monosaturated fats all appear to drive the accumulation of MDSC.
The studies reported here identify a new mechanism by which leptin, a product of adipose tissue which is overexpressed in obesity, impacts the immune system and thereby modulates both metabolic dysfunction and tumor growth. Leptin has previously been shown to drive multiple immune functions, such as the proliferation of circulating naive T cells, 39 inhibition of proliferation of T memory cells, 40 antagonism of T regulatory cells, 46 impairment of NK cytotoxicity, 47 maturation of DC and DC function, 48 inhibition of neutrophil chemotaxis and infiltration, 49, 50 and induction of mast cells producing inflammatory mediators IL-1 , TNF-, and IL-6 which in turn polarize macrophages toward an M1 phenotype. 51 Enhancement of MDSC accumulation and increasing MDSC-suppressive potency are now added to the list of functions regulated by leptin.
It has been reported that MDSC levels increase as mice age. 33, 52, 53 Limited data in older cancer patients suggest that MDSC levels also increase in humans as they age. 54 However, in many cases, body mass also increases with ageing, raising the possibility that the 
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